Pay in 4 interest-free payments of $6.89 Learn more
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9
Notable anticipated approvals for fourth quarter 2025 include: First oral GLP-1 for chronic weight management Two gene therapies for rare conditions An agent for obstructive hypertrophic cardiomyopathy Next generation option for severe eosinophilic asthma New prodrug for children with achondroplasia First-in-class therapy for a rare condition marked by severely high triglycerides A monoclonal antibody for an inflammatory kidney condition A targeted oral agent for advanced lung cancer We hope you enjoy the report
What triggers the release of GLP-1
A single 30mg vial at 12mg weekly lasts longer than a 20mg vial, reducing your reconstitution frequency and keeping your protocol cleaner
A primary care visit can help sort simple causes from warning signs
DPP-4 inhibitors carry a minimal risk of hypoglycemia and gastrointestinal symptoms
US$ 26.03
US$ 26.25
US$ 21.72
